Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F19%3AN0000092" target="_blank" >RIV/00098892:_____/19:N0000092 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/19:00111746 RIV/61989592:15110/19:73598732 RIV/61988987:17110/19:A21025BX

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S1043466617300820?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1043466617300820?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cyto.2017.03.016" target="_blank" >10.1016/j.cyto.2017.03.016</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls

Popis výsledku v původním jazyce

Objectives: Little is known about the role of adipokines in the pathogenesis of coronary artery disease in young patients. The aims of this study were to compare serum levels of adipokines and expression of adipokines in peripheral blood leukocytes in patients with premature coronary artery disease (CAD), metabolic syndrome and healthy individuals. Design and methods: Sixty-five patients with premature CAD (men 18-45 years old and women 18-55 years old) formed the study group. The control groups were 75 patients with metabolic syndrome and 50 healthy individuals. For each group, RNA expression in peripheral blood leukocytes was determined for 24 different adipokines and 11 adipokines were examined in serum. Results: In individuals with CAD, serum visfatin levels were significantly higher than in metabolic syndrome and healthy controls (2.3 vs. 1.6 vs. 0.7 mu g/L, P < 0.001) while both omentin-1 (92.9 vs. 587.0 vs. 552.3 mu g/L, P < 0.001) and ZAG2 (45.5 vs. 72.5 vs. 77.1 mg/L, P < 0.001) levels were lower. The receiver operating curve (ROC) analysis for testing the validity of these adipokines in the diagnosis of CAD compared to control groups provided the following areas under the curve (AUC): omentin-1 AUC 0.97 (cut-off <= 222 mu g/L), ZAG2 AUC 0.89 (cut-off <= 51.7 mg/L) and visfatin AUC 0.74 (cut-off >= 1.0 mu g/L) (P < 0.001 in all cases). Visfatin and omentin-1 serum levels did not differ between the acute phase of myocardial infarction and the chronic phase of CAD. In patients with CAD, we found no significant relation between mRNA expression and adipokine concentration. Conclusion: Serum omentin-1, visfatin and ZAG2 could serve as biomarkers of premature CAD in young apparently healthy people.

Název v anglickém jazyce

Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls

Popis výsledku anglicky

Objectives: Little is known about the role of adipokines in the pathogenesis of coronary artery disease in young patients. The aims of this study were to compare serum levels of adipokines and expression of adipokines in peripheral blood leukocytes in patients with premature coronary artery disease (CAD), metabolic syndrome and healthy individuals. Design and methods: Sixty-five patients with premature CAD (men 18-45 years old and women 18-55 years old) formed the study group. The control groups were 75 patients with metabolic syndrome and 50 healthy individuals. For each group, RNA expression in peripheral blood leukocytes was determined for 24 different adipokines and 11 adipokines were examined in serum. Results: In individuals with CAD, serum visfatin levels were significantly higher than in metabolic syndrome and healthy controls (2.3 vs. 1.6 vs. 0.7 mu g/L, P < 0.001) while both omentin-1 (92.9 vs. 587.0 vs. 552.3 mu g/L, P < 0.001) and ZAG2 (45.5 vs. 72.5 vs. 77.1 mg/L, P < 0.001) levels were lower. The receiver operating curve (ROC) analysis for testing the validity of these adipokines in the diagnosis of CAD compared to control groups provided the following areas under the curve (AUC): omentin-1 AUC 0.97 (cut-off <= 222 mu g/L), ZAG2 AUC 0.89 (cut-off <= 51.7 mg/L) and visfatin AUC 0.74 (cut-off >= 1.0 mu g/L) (P < 0.001 in all cases). Visfatin and omentin-1 serum levels did not differ between the acute phase of myocardial infarction and the chronic phase of CAD. In patients with CAD, we found no significant relation between mRNA expression and adipokine concentration. Conclusion: Serum omentin-1, visfatin and ZAG2 could serve as biomarkers of premature CAD in young apparently healthy people.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CYTOKINE

ISSN

1043-4666

e-ISSN

1096-0023

Svazek periodika

122

Číslo periodika v rámci svazku

SI (October)

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

154017

Kód UT WoS článku

000488662600003

EID výsledku v databázi Scopus

2-s2.0-85017464660